StockNews.com started coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the biotechnology company’s stock. Several other analysts have also recently issued reports on MRTX. Stifel Nicolaus reaffirmed a hold rating and issued a $59.00 price target (down from $83.00) […]
StockNews.com began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note released on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Other research analysts have also recently issued research reports about the company. Jefferies Financial Group cut Mirati Therapeutics from a buy rating to a […]
Mirati Therapeutics (NASDAQ:MRTX) Rating Reiterated by Citigroup theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Mirati Therapeutics (NASDAQ:MRTX) Earns "Neutral" Rating from Citigroup themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 4,740,000 shares, a decrease of 22.2% from the November 15th total of 6,090,000 shares. Based on an average trading volume of 2,270,000 shares, […]